According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock reached 20% for three consecutive trading days on August 6, 7, and 10, 2026, which is an abnormal fluctuation. It went up and down for five consecutive trading days from August 4 to 10, with an increase of 60.97%. In the first quarter of 2026, the company's revenue was 67.1829 million yuan, down 30.68% year on year; net profit was 6.6427 million yuan, down 67.94% year on year. The company's fundamentals have not changed, and the stock price has deviated from fundamentals. The latest rolling price-earnings ratio is significantly higher than the industry level, reminding investors to be aware of risks.

According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock reached 20% for three consecutive trading days on August 6, 7, and 10, 2026, which is an abnormal fluctuation. It went up and down for five consecutive trading days from August 4 to 10, with an increase of 60.97%. In the first quarter of 2026, the company's revenue was 67.1829 million yuan, down 30.68% year on year; net profit was 6.6427 million yuan, down 67.94% year on year. The company's fundamentals have not changed, and the stock price has deviated from fundamentals. The latest rolling price-earnings ratio is significantly higher than the industry level, reminding investors to be aware of risks.